OneOme's economic value white paper

Fill out the form to access your copy of OneOme's economic value white paper and to have a copy emailed to you.

The OneOme RightMed® pharmacogenomic solution, co­-developed with Mayo Clinic, analyzes a patient’s DNA to predict how he or she is likely to respond to hundreds of medications, which may lead to fewer side effects, less trial­-and­-error, and more effective prescriptions.

By filling out the form, you will get a copy of OneOme’s economic value white paper, which:

  • Features a Markov cost analysis of optimizing antidepressant therapy

  • Discusses the cost burden of major depression and analyzes how a pharmacogenomic test may potentially mitigate this burden

  • Presents potential direct cost savings to payers when patients with major depression are given a pharmacogenomic test

The OneOme RightMed® pharmacogenomic solution, co­-developed with Mayo Clinic, analyzes a patient’s DNA to predict how he or she is likely to respond to hundreds of medications, which may lead to fewer side effects, less trial­-and­-error, and more effective prescriptions.

Your copy of OneOme’s economic value white paper:

  • Features a Markov cost analysis of optimizing antidepressant therapy

  • Discusses the cost burden of major depression and analyzes how a pharmacogenomic test may potentially mitigate this burden

  • Presents potential direct cost savings to payers when patients with major depression are given a pharmacogenomic test